IFN-γ通过激活红系细胞中JAK/STAT通路增加δ-珠蛋白基因表达
本研究在红系细胞中探讨干扰素γ(IFN-γ)对δ-珠蛋白表达的调控机制。IFN-γ和IFN-β均增强δ-珠蛋白表达并激活JAK/STAT通路,IFN-γ作用强于IFN-β。抑制JAK/STAT通路或突变δ-珠蛋白启动子IRF-1/STAT2及邻近STAT结合位点可减弱IFN-γ诱导的δ-珠蛋白表达,提示IFN-γ可能对镰状细胞病患者具有治疗潜力。
要点
- IFN-γ和IFN-β增强红系细胞δ-珠蛋白表达并激活JAK/STAT通路,IFN-γ作用更强。
- JAK1/2抑制剂或靶向JAK1、JAK2、STAT1、STAT3的siRNA降低基础和IFN-γ诱导的δ-珠蛋白表达。
- δ-珠蛋白启动子IRF-1/STAT2及邻近STAT结合位点突变或去除可损害IFN-γ诱导的启动子活性。
核心结论
- 阐明特定分子诱导δ-珠蛋白表达的机制,提示IFN-γ可能对镰状细胞病患者具有治疗潜力。
- 筛选可诱导δ-珠蛋白的化合物可能为β-血红蛋白病提供新的药物策略。
研究设计与样本
- 研究在红系细胞中进行,包括来源于CD34+祖细胞的红系细胞和HBD-HiBiT敲入HUDEP2细胞。
主要发现
- IFN-γ和IFN-β显著增强红系细胞δ-珠蛋白表达并激活JAK/STAT信号通路,IFN-γ作用强于IFN-β。
- 在来源于CD34+祖细胞的红系细胞中,IFN-γ不仅增加δ-珠蛋白表达,还促进分化,经定量聚合酶链反应、蛋白质印迹、高效液相色谱和流式细胞术证实。
- 在HBD-HiBiT敲入HUDEP2细胞中,JAK1/2抑制剂(AZD1840或芦可替尼)或靶向JAK1、JAK2、STAT1或STAT3的小干扰RNA显著降低基础和IFN-γ诱导的δ-珠蛋白表达。
- δ-珠蛋白启动子中推定的IRF-1/STAT2结合位点(-265至-242)及邻近STAT结合位点(-243至-231)突变或去除可损害IFN-γ诱导的δ-启动子活性。
- 染色质免疫沉淀实验证实IFN-γ处理后干扰素调节因子1(IRF-1)和STAT1结合增强。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell disease (SCD) and β-thalassemia, caused by mutations or deletions in the β-globin gene, are among the most prevalent genetic disorders worldwide, significantly affecting global health and mortality. Recently, reactivation of δ-globin gene expression has been proposed as a potential therapeutic strategy for these conditions. In this study, we found that interferon gamma (IFN-γ) and IFN-β significantly enhance δ-globin expression and activate the JAK/STAT signaling pathway in erythroid cells, with IFN-γ exerting a stronger effect than IFN-β. In erythroid cells derived from CD34+ progenitors, IFN-γ not only increased δ-globin expression but also promoted differentiation, as confirmed by quantitative polymerase chain reaction, western blotting, high-performance liquid chromatography, and flow cytometry. Inhibition of the JAK/STAT pathway, either through a JAK1/2 inhibitor (AZD1840 or ruxolitinib) or via small interfering RNAs targeting JAK1, JAK2, STAT1, or STAT3, significantly decreased both basal and IFN-γ-induced δ-globin expression in HBD-HiBiT knockin HUDEP2 cells. Mutation or removal of the putative IRF-1/STAT2 binding site (-265 to -242) and the adjacent STAT binding site (-243 to -231) in the δ-globin promoter impaired IFN-γ-induced δ-promoter activity. Chromatin immunoprecipitation assays confirmed enhanced binding of interferon regulatory factor 1 (IRF-1) and STAT1 upon IFN-γ treatment. Our elucidation of the mechanism by which a specific molecule induces δ-globin expression suggests that IFN-γ may hold therapeutic potential for patients with SCD, and that screening for compounds that can induce δ-globin could offer a novel pharmaceutical strategy for treating β-hemoglobinopathies.
引用
- Zhu J, Chin K, Zou J, et al. IFN-γ increases δ-globin gene expression through activation of the JAK/STAT pathway in erythroid cells. Blood. 2026. PMID: 41284617. doi:10.1182/blood.2025029969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。